Top Stories
-
The goal of the ADRC HS Scholars Program is to reach talented young people from backgrounds underrepresented in science and medicine, and to encourage and inspire them toward careers in these fields.
-
Scott A. Small, MD, Boris & Rose Katz Professor of Neurology and Director of the Alzheimer's Disease Research Center, comments about how memories are encoded.
-
Scott A. Small, MD, Boris and Rose Katz Professor of Neurology, talks about why it is important to make an appointment with a doctor when you experience memory problems.
-
Adam M. Brickman, PhD, Professor of Neuropsychology, and Scott A. Small, MD, Boris and Rose Katz Professor of Neurology, discuss their study that examined health benefits of flavanol-rich diet
Topic
Latest News
- May 29, 2023
Scott Small, MD, Boris & Rose Katz Professor of Neurology and Director & Alzheimer's Disease Research Center at CUIMC talks about the study that examined flavanols levels and memory loss
Topic
- February 27, 2023
Many people live years or even decades with dementia, which causes death. Researching the symptoms and causes can dramatically help dementia care and prevention.
Topic
- August 31, 2022
Dr. James M. Noble is an associate professor of neurology and dementia specialist in the Division of Aging and Dementia.
Topic
- July 5, 2022
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
Topic
- May 22, 2022
Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease.
Topic
- April 28, 2022
A recent look inside a baby zebrafish's transparent brain offers clues to how we remember and how we forget.
Topic
- December 28, 2021
Columbia research seven years in the making highlights potential therapeutic target for neurodegenerative disease
Topic
- July 8, 2021
There is a robust market for books that praise our seemingly feeble habits of mind.
Topic
- June 28, 2021
The federal health insurance program may limit who can get the drug, which Biogen priced at $56,000 a year, to limit the financial impact
Topic
- June 8, 2021
On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.
Topic
